IDEXX Laboratories, Inc. $IDXX Shares Acquired by Inspire Investing LLC

Inspire Investing LLC raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 47.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,501 shares of the company’s stock after acquiring an additional 4,033 shares during the period. IDEXX Laboratories accounts for about 0.8% of Inspire Investing LLC’s investment portfolio, making the stock its 18th biggest holding. Inspire Investing LLC’s holdings in IDEXX Laboratories were worth $8,457,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Investment Management Corp of Ontario boosted its stake in IDEXX Laboratories by 6.7% in the fourth quarter. Investment Management Corp of Ontario now owns 52,069 shares of the company’s stock valued at $35,226,000 after acquiring an additional 3,274 shares during the period. Gotham Asset Management LLC boosted its stake in IDEXX Laboratories by 22.8% in the fourth quarter. Gotham Asset Management LLC now owns 59,738 shares of the company’s stock valued at $40,415,000 after acquiring an additional 11,095 shares during the period. Evolve Private Wealth LLC acquired a new position in IDEXX Laboratories in the fourth quarter valued at approximately $419,000. First Manhattan CO. LLC. boosted its stake in IDEXX Laboratories by 139.9% in the fourth quarter. First Manhattan CO. LLC. now owns 2,171 shares of the company’s stock valued at $1,469,000 after acquiring an additional 1,266 shares during the period. Finally, Capitolis Liquid Global Markets LLC acquired a new position in IDEXX Laboratories in the fourth quarter valued at approximately $1,780,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

IDXX has been the subject of a number of research reports. UBS Group decreased their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Stifel Nicolaus decreased their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Citigroup initiated coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price for the company. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Stock Performance

IDXX opened at $546.09 on Thursday. The business’s 50 day moving average is $562.51 and its 200-day moving average is $622.66. The stock has a market cap of $43.08 billion, a PE ratio of 40.21, a price-to-earnings-growth ratio of 3.13 and a beta of 1.55. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the previous year, the company posted $2.91 earnings per share. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.